BELLICUM PHARMACEUTICALS, INC

Profile

Company Names

BELLICUM PHARMACEUTICALS, INC

Addresses

2130 WEST HOLCOMBE BOULEVARD, SUITE 850, HOUSTON, TX 77030

2130 W. HOLCOMBE BLVD., SUITE 850, HOUSTON, TX 77030

6400 FANNIN, SUITE 2300, HOUSTON, TX 77030

Phone Numbers

(832) 384-1100
7133416470

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

2004

State Incorporated:

DE

Total Amount Raised:

$116,931,722.00

Number of Funding Rounds:

5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2014-08-22 
$94,357,588.00 
$94,357,588.00 
$0.00 
Equity 
4
2011-11-09 
$19,649,134.00 
$35,000,000.00 
$15,350,866.00 
Equity 
3
2010-09-30 
$1,175,000.00 
$3,000,000.00 
$1,825,000.00 
Debt 
2
2009-10-16 
$1,250,000.00 
$2,500,000.00 
$1,250,000.00 
Debt 
1
2009-03-25 
$500,000.00 
$1,500,000.00 
$1,000,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JAMES 
F. 
BROWN 
DIRECTOR
INFRASTRUCT SECURITY INC   |  DOWLEY SECURITY SYSTEMS, INC.   |  BELLICUM PHARMACEUTICALS, INC
THOMAS 
 
FARRELL 
EXECUTIVE OFFICER, DIRECTOR
BELLICUM PHARMACEUTICALS, INC   |  IMMUNEBRIDGE INC.
THOMAS 
J. 
FARRELL 
EXECUTIVE OFFICER, DIRECTOR
BELLICUM PHARMACEUTICALS, INC   |  ARTIVA BIOTHERAPEUTICS, INC.
FRANK 
 
MCGUYER 
DIRECTOR
BELLICUM PHARMACEUTICALS, INC
ANNEMARIE 
 
MOSELEY 
EXECUTIVE OFFICER
SERNOVA CORP.   |  BELLICUM PHARMACEUTICALS, INC
KEN 
 
MOSELEY 
EXECUTIVE OFFICER
BELLICUM PHARMACEUTICALS, INC
JOSEPH 
 
SENESAC 
EXECUTIVE OFFICER
BELLICUM PHARMACEUTICALS, INC
KEVIN 
 
SLAWIN 
EXECUTIVE OFFICER, DIRECTOR
BELLICUM PHARMACEUTICALS, INC   |  K2 BIOLABS, LLC   |  RAPHA CAPITAL BIOVENTURES FUND I, LP   |  RAPHA CAPITAL PE LIFE SCIENCES FUND VI, LP   |  K2 BIOLABS, INC.
KEVIN 
M. 
SLAWIN 
EXECUTIVE OFFICER, DIRECTOR
BELLICUM PHARMACEUTICALS, INC
DAVID 
 
SPENCER 
EXECUTIVE OFFICER
BELLICUM PHARMACEUTICALS, INC   |  BIOLEX THERAPEUTICS, INC.
DAVID 
M. 
SPENCER 
EXECUTIVE OFFICER
BELLICUM PHARMACEUTICALS, INC
DENNIS 
K. 
STONE 
DIRECTOR
NUCLEA BIOTECHNOLOGIES, INC.   |  BELLICUM PHARMACEUTICALS, INC   |  SOLITON, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2014-09-03
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2014-08-22 
2013-10-16
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2011-11-09 
2012-03-22
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2011-11-09 
2010-10-25
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Debt 
2010-09-30 
2009-10-21
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Debt 
2009-10-16 
2009-03-31
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2009-03-25 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
JEFFERIES LLC
2347